A box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes made by Lilly is seen at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS
Oct 27 (Reuters) – Eli Lilly (LLY.N), and expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported, on Sunday.
The drugmaker has received approval from the Hong Kong government to sell its tirzepatide injections — branded as Mounjaro — in a device called Kwikpen for both long-term weight management and type 2 diabetes, Eli Lilly told Bloomberg in a statement.
Tirzepatide is the active ingredient in the U.S. firm’s diabetes drug Mounjaro and weight-loss drug Zepbound.
The company received approval from Chinese regulators for its weight-loss drug tirzepatide in July, further intensifying competition with Danish rival Novo Nordisk (NOVOb.CO), in the key Asian market.
Novo Nordisk and Eli Lilly are racing to increase production in a weight-loss market estimated to reach at least $100 billion globally by the end of the decade.
Both companies’ obesity treatments belong to a class of drugs originally developed for diabetes known as GLP-1 agonists.
Reporting by Jahnavi Nidumolu and Devika Nair in Bengaluru; Editing by Subhranshu Sahu
